| Compound | Cerebrolysin |
|---|---|
| Category | Porcine brain peptide preparation |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Cerebrolysin is catalogued here as a porcine brain peptide preparation and graded at the "Clinical-stage" evidence tier. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A porcine brain-derived mixture of low-molecular peptides and amino acids, approved in dozens of countries (not including the US) for stroke and cognitive disorders.
Mechanism of Action
Proposed neurotrophic and neuroprotective effects are attributed to the mixture as a whole — a pharmacology that resists single-molecule analysis.
Research and Evidence
A substantial trial literature exists including randomized stroke trials, with heterogeneous results; regulators in different countries have reached different conclusions on evidence sufficiency.
Safety and Side Effects
Post-marketing experience in registered markets exists; rare hypersensitivity is the main flagged risk. US FDA has not approved it.
Frequently Asked Questions
What is the evidence tier of Cerebrolysin?
Cerebrolysin is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Cerebrolysin an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Cerebrolysin?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered Cerebrolysin studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.